{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:21Z","timestamp":1786979901133,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LTGY24H160031"],"award-info":[{"award-number":["LTGY24H160031"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04161-6","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T02:25:57Z","timestamp":1757557557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study"],"prefix":"10.1007","volume":"74","author":[{"given":"Xingmao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangliu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingquan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"4161_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4161_CR2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW et al (2014) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 134(3):622\u2013628","journal-title":"Int J Cancer"},{"issue":"2","key":"4161_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/cas.14231","volume":"111","author":"QY Chen","year":"2020","unstructured":"Chen QY, Zhong Q, Zhou JF, Qiu XT, Dang XY, Cai LS et al (2020) Conditional survival and recurrence of remnant gastric cancer after surgical resection: a multi-institutional study. Cancer Sci 111(2):502\u2013512","journal-title":"Cancer Sci"},{"issue":"10251","key":"4161_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet 396(10251):635\u2013648","journal-title":"Lancet"},{"issue":"3","key":"4161_CR5","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD (2021) Current treatment and recent progress in gastric cancer. CA Cancer J Clin 71(3):264\u2013279","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4161_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol 26(1):141\u2013148","journal-title":"Ann Oncol"},{"issue":"9742","key":"4161_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u2013697","journal-title":"Lancet"},{"issue":"2","key":"4161_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","volume":"19","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y (2016) Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer 19(2):329\u2013338","journal-title":"Gastric Cancer"},{"issue":"8","key":"4161_CR9","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s00432-021-03516-7","volume":"147","author":"H Ohnuma","year":"2021","unstructured":"Ohnuma H, Sato Y, Onoyama N, Hamaguchi K, Hayasaka N, Sato M et al (2021) Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: a propensity score-matching analysis. J Cancer Res Clin Oncol 147(8):2385\u20132396","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"4161_CR10","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.ejso.2015.04.021","volume":"41","author":"J Kinoshita","year":"2015","unstructured":"Kinoshita J, Fushida S, Tsukada T, Oyama K, Okamoto K, Makino I et al (2015) Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer. Eur J Surg Oncol 41(10):1354\u20131360","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"4161_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G et al (2022) International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 6(2):227\u2013240","journal-title":"Ann Gastroenterol Surg"},{"issue":"2","key":"4161_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with her2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (attraction-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(2):234\u2013247","journal-title":"Lancet Oncol"},{"issue":"2","key":"4161_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"N Boku","year":"2019","unstructured":"Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW et al (2019) Safety and efficacy of nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (attraction-4). Ann Oncol 30(2):250\u2013258","journal-title":"Ann Oncol"},{"issue":"28","key":"4161_CR14","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","volume":"36","author":"YY Janjigian","year":"2018","unstructured":"Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P et al (2018) Checkmate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36(28):2836\u20132844","journal-title":"J Clin Oncol"},{"issue":"10294","key":"4161_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (checkmate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27\u201340","journal-title":"Lancet"},{"issue":"21","key":"4161_CR16","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L et al (2023) Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the orient-16 randomized clinical trial. JAMA 330(21):2064\u20132074","journal-title":"JAMA"},{"issue":"2","key":"4161_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"key":"4161_CR18","unstructured":"Common terminology criteria for adverse events version 3.0 (ctcae v.3.0) available from. http:\/\/ctep.Cancer.Gov\/protocoldevelopment\/electronic_applications\/ctc.Htm"},{"key":"4161_CR19","doi-asserted-by":"crossref","unstructured":"Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 24 (1) 1-21","DOI":"10.1007\/s10120-020-01042-y"},{"issue":"2","key":"4161_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205\u2013213","journal-title":"Ann Surg"},{"issue":"7","key":"4161_CR21","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521\u20131530","journal-title":"Cancer"},{"issue":"6","key":"4161_CR22","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s10120-023-01431-z","volume":"26","author":"X Huang","year":"2023","unstructured":"Huang X, Fang J, Huang L, Chen H, Chen H, Chai T et al (2023) Sox combined with sintilimab versus sox alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis. Gastric Cancer 26(6):1040\u20131050","journal-title":"Gastric Cancer"},{"issue":"7","key":"4161_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann M, Stoss O, Shi D, B\u00fcttner R, van de Vijver M, Kim W et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7):797\u2013805","journal-title":"Histopathology"},{"issue":"3","key":"4161_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10120-016-0633-1","volume":"20","author":"Y Sato","year":"2017","unstructured":"Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K et al (2017) Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer 20(3):517\u2013526","journal-title":"Gastric Cancer"},{"issue":"2","key":"4161_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10120-017-0738-1","volume":"21","author":"K Yamaguchi","year":"2018","unstructured":"Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y et al (2018) The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer 21(2):315\u2013323","journal-title":"Gastric Cancer"},{"key":"4161_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108111","volume":"236","author":"DR Principe","year":"2022","unstructured":"Principe DR, Kamath SD, Korc M, Munshi HG (2022) The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. Pharmacol Ther 236:108111","journal-title":"Pharmacol Ther"},{"issue":"4","key":"4161_CR27","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-21-0888","volume":"12","author":"R Kim","year":"2022","unstructured":"Kim R, An M, Lee H, Mehta A, Heo YJ, Kim KM et al (2022) Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer. Cancer Discov 12(4):984\u20131001","journal-title":"Cancer Discov"},{"issue":"7890","key":"4161_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P, Li N, Lonardi S, Kolesnik O et al (2021) The keynote-811 trial of dual pd-1 and her2 blockade in her2-positive gastric cancer. Nature 600(7890):727\u2013730","journal-title":"Nature"},{"key":"4161_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000738","author":"H Liang","year":"2023","unstructured":"Liang H, Yan X, Chen X, Li Z, Qiu Y, Li F et al (2023) Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer. Int J Surg. https:\/\/doi.org\/10.1097\/JS9.0000000000000738","journal-title":"Int J Surg"},{"key":"4161_CR30","unstructured":"Jiafu Ji LS Ziyu Li Xiaotian Zhang Xiangyu Gao Yanqiao Zhang Bo Liu Yusheng Wang (2024) Ct006\u2014cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (g\/gej) adenocarcinoma (compassion-15). A randomized, double-blind, phase 3 trial. AACR annual meeting session CTPL02"},{"key":"4161_CR31","doi-asserted-by":"publisher","first-page":"927781","DOI":"10.3389\/fonc.2022.927781","volume":"12","author":"H Guo","year":"2022","unstructured":"Guo H, Ding P, Sun C, Yang P, Tian Y, Liu Y et al (2022) Efficacy and safety of sintilimab plus xelox as a neoadjuvant regimen in patients with locally advanced gastric cancer: a single-arm, open-label, phase II trial. Front Oncol 12:927781","journal-title":"Front Oncol"},{"key":"4161_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003635","author":"H Jiang","year":"2022","unstructured":"Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D et al (2022) Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003635","journal-title":"J Immunother Cancer"},{"key":"4161_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-023-01431-z","author":"X Huang","year":"2023","unstructured":"Huang X, Fang J, Huang L, Chen H, Chen H, Chai T et al (2023) Sox combined with sintilimab versus sox alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis. Gastric Cancer. https:\/\/doi.org\/10.1007\/s10120-023-01431-z","journal-title":"Gastric Cancer"},{"issue":"26","key":"4161_CR34","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) Pd-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509\u20132520","journal-title":"N Engl J Med"},{"issue":"10142","key":"4161_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, Di Bartolomeo M, Mandal\u00e0 M, Ryu MH et al (2018) Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (keynote-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392(10142):123\u2013133","journal-title":"Lancet"},{"issue":"1","key":"4161_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12672-022-00479-0","volume":"13","author":"\u00c1 Lima","year":"2022","unstructured":"Lima \u00c1, Sousa H, Medeiros R, Nobre A, Machado M (2022) Pd-l1 expression in EBV associated gastric cancer: a systematic review and meta-analysis. Discov Oncol 13(1):19","journal-title":"Discov Oncol"},{"issue":"3","key":"4161_CR37","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jnci\/djx213","volume":"110","author":"A Panda","year":"2018","unstructured":"Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T et al (2018) Immune activation and benefit from avelumab in EBV-positive gastric cancer. J Natl Cancer Inst 110(3):316\u2013320","journal-title":"J Natl Cancer Inst"},{"key":"4161_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007104","author":"G Randon","year":"2023","unstructured":"Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner SJ et al (2023) Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-007104","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4161_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Tougeron D, Piessen G, de la Fouchardi\u00e8re C, Louvet C, Adenis A et al (2023) Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the gercor neonipiga phase II study. J Clin Oncol 41(2):255\u2013265","journal-title":"J Clin Oncol"},{"key":"4161_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040805","author":"H Kawakami","year":"2021","unstructured":"Kawakami H, Hironaka S, Esaki T, Chayama K, Tsuda M, Sugimoto N et al (2021) An investigator-initiated phase 2 study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability-high advanced gastric or esophagogastric junction cancer (no limit, wjog13320g\/ca209-7w7). Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13040805","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4161_CR41","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24(9):1449\u20131458","journal-title":"Nat Med"},{"issue":"1","key":"4161_CR42","doi-asserted-by":"publisher","first-page":"2135819","DOI":"10.1080\/2162402X.2022.2135819","volume":"11","author":"X Tang","year":"2022","unstructured":"Tang X, Li M, Wu X, Guo T, Zhang L, Tang L et al (2022) Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer. Oncoimmunology 11(1):2135819","journal-title":"Oncoimmunology"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04161-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04161-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04161-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:10:08Z","timestamp":1760962208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04161-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4161"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04161-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"20 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Zhejiang Cancer Hospital (approval number: IRB-2022\u2013278) and was conducted according to the Declaration of Helsinki. Informed consent was obtained from each patient enrolled in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"302"}}